Check-Cap

What Check-Cap does

Check-Cap Ltd. (NASDAQ: MBAI, formerly CHEK) is an Israeli-domiciled public company undergoing a strategic transformation through its pending merger with MBody AI Corp., a Nevada-based privately held embodied AI company. The transaction, announced via a definitive agreement in September 2025 and approved by over 98% of Check-Cap shareholders in November 2025, is structured as a 90/10 equity split favoring MBody AI shareholders and is expected to close in H2 2026, at which point the combined entity will be renamed MBody AI Ltd. Check-Cap was originally founded in 2004 to develop the C-Scan® System, an ingestible ultra-low-dose X-ray capsule for preparation-free colorectal cancer screening; development of C-Scan was discontinued in June 2023, and the company has been operating without material product revenue while evaluating strategic alternatives.

The post-merger core offering is the MBody AI Orchestrator™, a proprietary hardware-agnostic embodied AI platform that integrates with heterogeneous robotic and sensor-based systems to deliver real-time data intelligence, dynamic task and route optimization, continuous on-site learning, and multi-site fleet intelligence from a single pane of glass. The platform targets enterprise customers across six verticals — hospitality, offices, warehouses, healthcare, logistics, and data centers — with a disclosed Fortune 500 gaming and hospitality operator expanding its deployment across multiple properties from less than 10% of national footprint. IP coverage consists of six provisional patents across the architecture stack from perception to policy.

The business model is enterprise field sales to Fortune 500 and blue-chip clients, with pilots scaling into national multi-property deployments and pricing conducted on a quote-based, undisclosed basis. Revenue mechanics are expected to be a mix of managed services / platform deployments with implied per-robot or per-site licensing of the hardware-agnostic intelligence layer. Legacy Check-Cap is pre-revenue, MBody AI revenue is not publicly disclosed, and pricing or ARR metrics are not available. As of February 2026, the company secured up to $30 million in discretionary growth capital via an equity line of credit with ARC Group International Inc. to fund scaling of the MBody AI commercial platform pending merger close.

Name

Check-Cap

Legal name

Check-Cap Ltd.

Website

https://check-cap.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

Check-Cap Ltd. (NASDAQ: MBAI) is an Israeli public company pending a merger with MBody AI Corp. (expected H2 2026 close) to become a publicly traded embodied AI platform provider. Its Orchestrator™ software delivers hardware-agnostic AI orchestration for autonomous robotic fleets serving Fortune 500 enterprise clients across hospitality, offices, warehouses, healthcare, logistics, and data centers.

Ownership category

akta.pro rank

Product category

Embodied AI Platform

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Instruments and Related Products Manufacturing for Measuring, Displaying, and Controlling Industrial Process Variables (334513)

SIC

Surgical & Medical Instruments & Apparatus (3841), Search, Detection, Navagation, Guidance, Aeronautical Sys (3812), Industrial Instruments For Measurement, Display, And Control (3823)

akta.pro primary industry

End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management) (HDAEANAA)

akta.pro secondary industry

Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)

Keywords

• Embodied AI platform
• Enterprise robotics orchestration
• Autonomous workforce software
• Hardware-agnostic AI
• Fleet intelligence software

Headquarters

HQ city

Isfiyeh

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pre-revenue / Clinical-Stage (Legacy Check-Cap): Check-Cap historically operated as a clinical-stage medical diagnostics company developing the C-Scan® System, which is not approved in the United States and remains an investigational device. The company discontinued C-Scan development in June 2023 and has been evaluating strategic alternatives, generating negligible recurring product revenue.
2. Enterprise Embodied AI Deployments (MBody AI): Upon completion of the MBody AI merger, revenue is expected to be generated through enterprise-grade deployments of the MBody AI Orchestrator platform with Fortune 500 and blue-chip clients across hospitality, offices, warehouses, healthcare, logistics, and data centers. MBody AI reports existing and expanding Fortune 500 deployments (e.g., national rollout with a Fortune 500 gaming and hospitality operator across multiple properties) that drive recurring platform revenue as pilots scale into national footprints.
3. Hardware-Agnostic Platform Licensing (Implied): As the Orchestrator platform is hardware-agnostic and integrates with any robotic platform, future revenue streams may include per-robot or per-site licensing of the intelligence layer, supplementing deployment services with recurring software-like economics.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

Check-Cap is transforming via its pending merger with MBody AI Corp. into a publicly traded embodied AI company. Its future core offering is the MBody AI Orchestrator™, a proprietary, hardware-agnostic AI platform that integrates robotic and sensor-based systems across hospitality, offices, warehouses, healthcare, logistics, and data centers, delivering real-time data intelligence, dynamic task and route optimization, and multi-site fleet autonomy. The legacy C-Scan® ingestible X-ray capsule for preparation-free colorectal cancer screening had its development discontinued in June 2023, with associated IP retained.

Product overview

Check-Cap Ltd.'s offering has shifted from a single-product clinical-stage medical diagnostics platform centered on the C-Scan® System (an ingestible X-ray capsule for preparation-free colorectal cancer screening, now discontinued for development as of June 2023) toward a platform-plus-modules architecture anchored by MBody AI's Orchestrator™ platform. Following the definitive merger agreement signed in September 2025, the C-Scan® System is retained as legacy intellectual property while the future product portfolio — comprising the MBody AI Orchestrator™ core platform and its enterprise-grade autonomous-workforce capabilities for hospitality, offices, warehouses, and healthcare — will become the combined entity's primary offering upon the merger's expected H2 2026 close.

Differentiator

Problem solved

Functional benefit

Brands

• C-Scan® System: An ingestible X-ray capsule designed to generate 3D structural maps of the inner lining of the colon for preparation-free colorectal cancer screening. Not approved in the United States; was an investigational device before development was discontinued in June 2023.

Products and services

• MBody AI Orchestrator™ Hardware-agnostic, proprietary embodied AI platform that integrates robotic and sensor-based systems to deliver real-time data intelligence, dynamic task and route optimization, continuous on-site learning, and multi-site fleet intelligence for Fortune 500 and blue-chip enterprise clients across hospitality, offices, warehouses, healthcare, logistics, and data center operations.
• C-Scan® System Ingestible ultra-low-dose X-ray capsule designed to generate 3D structural maps of the colon's inner lining as it passes naturally through the gastrointestinal tract, intended for preparation-free colorectal cancer screening without bowel preparation, sedation, or dietary restrictions. Investigational device, not approved in the United States.

Quantifiable outcome

• Up to 80% labor savings on repetitive tasks
• +3 more outcomes

Named customers1 record

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

Six partnerships are on record, tiered minor and flagship.

• Keystone DentalminorStrategic or Co-development Partner · 1 May 2026According to a May 2026 third-party news analysis, Check-Cap was reported to have agreed to merge with US-based Keystone Dental through a reverse merger and delist from Nasdaq, with Keystone shareholders expected to own the majority of the combined entity operating as a dental implants and prosthetics supplier. This report conflicts with primary first-party sources that confirm the MBody AI merger as the active transaction; the Keystone Dental report appears inconsistent with Check-Cap's official website and IR disclosures and is not corroborated in primary SEC filings.
• Equiniti Trust Company, LLCminorOthers · 1 December 2025Equiniti Trust Company, LLC is Check-Cap's transfer agent for ordinary shares listed on the NASDAQ Capital Market. Located at 6201 15th Avenue, Brooklyn, NY 11219, with U.S. toll-free line (800) 937-5449 and international line (718) 921-8124. Provides shareholder services via the Equiniti Shareholder Portal.
• MBody AI Corp.flagshipStrategic or Co-development Partner · 1 September 2025In September 2025, Check-Cap entered into a definitive merger agreement with MBody AI Corp., a privately held Nevada-based embodied AI company. The merger has been approved by over 98% of Check-Cap shareholders and is structured as a 90/10 equity split in favor of MBody AI shareholders. Upon closing in H2 2026, the combined company will be renamed MBody AI Ltd. and continue trading on NASDAQ under the ticker MBAI. The transaction will transform Check-Cap from a clinical-stage medical diagnostics company into a leading publicly traded embodied AI company.
• Paul Hastings LLPminorImplementation/ SI/ Consulting Partner · 1 September 2025Paul Hastings LLP serves as Check-Cap's legal advisor in the United States for the MBody AI merger transaction. Engaged in connection with the definitive merger agreement signed in September 2025.
• Rimon PCminorImplementation/ SI/ Consulting Partner · 1 September 2025Rimon PC serves as Check-Cap's legal advisor in Israel for the MBody AI merger transaction. Engaged in connection with the definitive merger agreement signed in September 2025.
• BCRG GroupminorImplementation/ SI/ Consulting Partner · 1 September 2025BCRG Group serves as Check-Cap's independent registered public accounting firm (auditor). Engaged to provide audit services for SEC filings related to the MBody AI merger.

Scale indicators10 records

Expansion highlights7 records

Direct peers

• SVT Robotics: SVT Robotics provides a hardware-agnostic robotics orchestration platform (SOFTBOT) that integrates and manages heterogeneous robotic fleets across warehouses and manufacturing, making it the most directly comparable pure-play peer to MBody AI's Orchestrator.
• Brain Corp: Brain Corp develops an AI platform that powers autonomous mobile robots deployed in retail, hospitality, warehouses, and healthcare environments — directly comparable to MBody AI's hardware-agnostic, AI-driven autonomous-workforce offering across similar end markets.
• Formant: Formant offers a cloud-based platform for managing and orchestrating heterogeneous robotic fleets with real-time telemetry, task optimization, and analytics — closely aligned with MBody AI Orchestrator's multi-site fleet intelligence and dynamic task/route optimization capabilities.
• InOrbit: InOrbit provides a Robot Operations Platform that orchestrates and observes autonomous robot fleets across enterprise deployments, with continuous learning and real-time optimization — a direct functional peer for MBody AI's embodied AI orchestration stack.
• Locus Robotics: Locus Robotics is a leader in autonomous warehouse robots, with large-scale enterprise deployments that generate the type of labor-savings ROI claims MBody AI emphasizes; comparable end customers and value proposition, though Locus focuses on its own hardware rather than a hardware-agnostic orchestrator.

Emerging players

• Vecna Robotics: Vecna Robotics builds autonomous mobile robots and orchestration software for warehousing, healthcare, and manufacturing, addressing the same repetitive-task labor savings use cases that MBody AI targets with its Orchestrator platform.

Broad incumbents

• Symbotic: Symbotic (NASDAQ: SYM) is an established publicly traded AI-powered warehouse automation platform serving large enterprise customers, providing a public-market comparable for the scale and AI-robotics thesis underpinning MBody AI's commercial platform.
• Berkshire Grey (SoftBank): Berkshire Grey (acquired by SoftBank in 2024) developed AI-enabled robotic solutions for fulfillment and logistics, validating the enterprise demand and acquisition logic that underpins the embodied AI thesis MBody AI is pursuing.
• C3.ai: C3.ai (NYSE: AI) is an enterprise AI software platform serving industrial, healthcare, and financial verticals — a broad-incumbent comparable for MBody AI's enterprise-AI go-to-market motion, although C3.ai focuses on analytics rather than embodied robotic control.
• UiPath: UiPath (NYSE: PATH) is an established enterprise automation platform with comparable Fortune 500 GTM motion and a recurring software-economics narrative, providing a public-market reference point for scaling AI-driven enterprise automation — albeit in software rather than physical robotics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/checkcap_
• LinkedInlinkedin.com/company/check-cap-ltd-

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds13 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Check-Cap